On Our Own Terms: A Conversation About Medical Aid in Dying, Dignity, and the Choices We're Afraid to Make
On August 5th, 2025, New York State became one of only a handful of states in the country where medical aid in dying is now legal.
For our community — people living with metastatic breast cancer — this is not an abstract policy debate. It's a deeply personal question about how we want to live, and how we want to die.
Developing Story: Your Cancer's DNA and the Trial Using It to Cure You with Dr. Pedram Razavi
What does it take to cure metastatic breast cancer? According to Dr. Pedram Razavi, it takes a blood test sensitive enough to find one cancer cell in a million, the courage to stop treatment when that signal disappears, and a trial designed to prove the paradigm wrong.
The HERizon-Breast Trial at Memorial Sloan Kettering is doing exactly that — and it's enrolling now.
This is one of the most science-rich episodes of Live from Stage 4 to date. We break down every term, every concept, and every implication in plain language so you don't need a medical degree to understand why this matters.
Symptoms Spotlight: Vaginal Dryness with Abigail Johnston and Melanie Sisk
"Nobody tells you about this part."
Vaginal dryness is one of the most common side effects of metastatic breast cancer treatment and one of the least talked about. In this episode, Abigail Johnston and Melanie speak candidly about what it is really like to navigate painful intimacy, shifting hormones, and the search for solutions while living with MBC
Developing Story: The Trial That Dares to Say Cure with Dr. Lior Braunstein
Dr. Lior Braunstein, radiation oncologist at Memorial Sloan Kettering, joins Victoria Goldberg and Ellen Landsberger to discuss the ARCHER trial — a groundbreaking study combining surgery and ablative radiation with standard HER2-targeted therapy in patients with oligometastatic HER2-positive breast cancer. The goal: eradicate every last cancer cell before resistance can emerge.
Developing Story: The Camizestrant Vote, Doctors Weigh In with Dr. Sarah Sammons & Dr. Neil Vasan
When the ODAC voted 6–3 against the camizestrant strategy, the headlines told you what happened — this episode tells you why. We're back for round two with Dr. Sarah Sammons, newly appointed Co-Leader of Breast Oncology at the University of Maryland Greenebaum Comprehensive Cancer Center, and Dr. Neil Vasan, Acting Chair of the ODAC and Director of Translational Research in Breast Cancer at NYU Langone Health, who sat in that room and cast one of the three yes votes. Alongside patient advocates Janice Cowden and Abigail Johnston, we break down the four FDA critiques that drove the vote, what the quality of life data showed and why regulators couldn't act on it, and what the FDA's new August 14th review deadline means for patients. Plus: why this science isn't going anywhere, and what ctDNA-guided treatment could look like in the very near future.
Developing Story: The Camizestrant Vote — When Your Blood Test Knows Before Your Scan Does
Six MBC patient advocates join host Victoria Goldberg to break down the FDA advisory committee's vote on camizestrant and the SERENA-6 trial. The panel unpacks what the vote really means, whether the science of molecular progression is ready for clinical practice, and why patient advocates need a seat at the table before trials are designed.
Thriving Together 2026: LBBC's MBC Conference Through Our Eyes
"You walk into a room full of people living with metastatic breast cancer and you just... break down. Not because it's sad — though it is — but because for the first time, you're not alone in it."
Twenty years in, LBBC's Thriving Together Conference is still doing what no other event in the MBC space does: bringing patients together not just to learn, but to find each other. In this episode, four MBC patients who attended the 2026 conference share what moved them, what the science is saying, and why they'll keep coming back.
Live Chat: SERD Surge with Dr. Sherry Shen
Host Victoria, with Dr. Sherry Shen and co-host Ellen, delivers a concise, patient-focused overview of oral SERDs in HR+ metastatic breast cancer—covering ESR1 mutations, key trials (evERA, SERENA‑6), FDA‑approved agents, side-effect management, and treatment implications. This is the first episode in our Live Chats series. Bonus clip: Rebecca Shatsky, MD, previews the evERA trial and her excitement about combining capivasertib with oral SERDs.
MBC Insiders: MBC Awareness Day and More
This is a special episode released Oct 13 for National Metastatic Breast Cancer Awareness Day. It is the first in our recurring series, we call “MBC Insiders.” We’ll explore the issues that matter most to people with MBC, including how the language clinicians and media use can harm or help, and candid conversations about progression and the idea of “cure.” Stay tuned for an important, honest discussion.